Register Now - Every Drop Matters: Reducing Product Loss in Sterile Filtration
|Webcasts|November 10, 2021

One-step Purification of 5’-DMT-on Oligonucleotides

**Wednesday, November 10, 2021 at 11am EST| 8am PST| 4pm GMT| 5pm CET** Unfold the power of oligonucleotide purification using a hydrophobic interaction resin in one-step chromatography method.

Register Free: https://www.biopharminternational.com/bp_w/5Tosoh

Event Overview:
Oligonucleotide purification and analysis methods have grown to meet the demands of expanded pipelines for oligonucleotide therapies in recent years. In this study, we will demonstrate the effectiveness of a one-step hydrophobic interaction chromatography (HIC) method for the purification of 5′-DMT-on oligonucleotides. We will detail a method that is designed for capture, and direct on-column cleavage, of 5′-DMT-on oligonucleotides. Additionally, we will detail analytical methods including reversed phase chromatography, analytical anion exchange chromatography, and size exclusion chromatography, which will ensure the high purity and quality of the final product.

  • An effective one-step purification of 5′-DMT-on oligonucleotides by hydrophobic interaction chromatography, with on-column DMT cleavage.
  • The selected phenyl-phase chemistry resin has a dynamic binding capacity >45 mg/mL resin for 5′-DMT-on oligonucleotides.
  • The on-column DMT cleavage method results in high product recovery while maintaining >95% product purity.

Key Learning Objectives:

  • Simplify purification of 5′-DMT-on oligonucleotides using a one-step hydrophobic interaction chromatography method.
  • Understand the power of hydrophobic interaction chromatography for 5′-DMT-on oligonucleotide purifications.
  • Learn how to ensure the high purity and best quality of the final product.

Who Should Attend:

  • Chromatographers, method developers and process engineers who are involved with the development and platform design for purification of oligonucleotides.
  • Process Engineers
  • Purification scientists

Speaker

William “Bill” Evans
Applications Scientist, Process Chromatography
Tosoh Bioscience LLC

Sponsor

Tosoh

Register Free: https://www.biopharminternational.com/bp_w/5Tosoh


Related to this article

The BioPharm Brief: Long-Term Survival Data for a PD-L1/4-1BB Bispecific, Celldex Exits Atopic Dermatitis, and a Fc-Fusion GLP-1 Goes Global
Leads Biolabs details survival data and 2027 ADC combination plans for its PD-L1/4-1BB bispecific opamtistomig, Celldex Therapeutics ends its atopic dermatitis program for anti-KIT antibody barzolvolimab after a phase 2 miss, and Innogen licenses its Fc-fusion GLP-1 receptor agonist efsubaglutide alfa to Arcera Life Sciences for international markets.
The BioPharm Brief: A Matrix-Targeting ADC in Head and Neck Cancer, an RNAi Approval in Myasthenia Gravis, and AbbVie Bets on AND-Gated Bispecifics
Pyxis Oncology’s EDB+FN-targeting ADC micvotabart pelidotin shows a 39% confirmed response rate in previously treated head and neck cancer, FDA approves Regeneron’s cemdisiran (Livsayis), an RNAi therapy Regeneron licensed from Alnylam Pharmaceuticals, as the first RNAi therapy for generalized myasthenia gravis, and AbbVie partners with DISCO Pharmaceuticals on AND-gated bispecifics for solid tumors.